These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

576 related articles for article (PubMed ID: 33165928)

  • 1. Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions.
    Cheng ML; Pectasides E; Hanna GJ; Parsons HA; Choudhury AD; Oxnard GR
    CA Cancer J Clin; 2021 Mar; 71(2):176-190. PubMed ID: 33165928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How liquid biopsies can change clinical practice in oncology.
    Siravegna G; Mussolin B; Venesio T; Marsoni S; Seoane J; Dive C; Papadopoulos N; Kopetz S; Corcoran RB; Siu LL; Bardelli A
    Ann Oncol; 2019 Oct; 30(10):1580-1590. PubMed ID: 31373349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liquid biopsy: unlocking the potentials of cell-free DNA.
    Chu D; Park BH
    Virchows Arch; 2017 Aug; 471(2):147-154. PubMed ID: 28466157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating tumor DNA: current implementation issues and future challenges for clinical utility.
    Hu Q; Chen L; Li K; Liu R; Sun L; Han T
    Clin Chem Lab Med; 2024 Oct; 62(11):2094-2110. PubMed ID: 38109307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell-Free DNA in the Liquid Biopsy Context: Role and Differences Between ctDNA and CTC Marker in Cancer Management.
    Fici P
    Methods Mol Biol; 2019; 1909():47-73. PubMed ID: 30580422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Interest of Circulating Tumor DNA in Oncology.
    Franczak C; Filhine-Tressarieu P; Broséus J; Gilson P; Merlin JL; Harlé A
    Arch Med Res; 2018 Jul; 49(5):297-305. PubMed ID: 30414710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system?
    Yang M; Forbes ME; Bitting RL; O'Neill SS; Chou PC; Topaloglu U; Miller LD; Hawkins GA; Grant SC; DeYoung BR; Petty WJ; Chen K; Pasche BC; Zhang W
    Ann Oncol; 2018 Feb; 29(2):311-323. PubMed ID: 29216340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
    Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
    Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liquid Biopsy: Emergence of an Alternative Cancer Detection Method.
    Law EW; Settell ML; Kurani SS; Eckert EC; Liu MC; Greenberg-Worisek AJ
    Clin Transl Sci; 2020 Sep; 13(5):845-847. PubMed ID: 32233063
    [No Abstract]   [Full Text] [Related]  

  • 10. Genetic profiling of cancer with circulating tumor DNA analysis.
    Lu L; Bi J; Bao L
    J Genet Genomics; 2018 Feb; 45(2):79-85. PubMed ID: 29502957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?
    Asante DB; Calapre L; Ziman M; Meniawy TM; Gray ES
    Cancer Lett; 2020 Jan; 468():59-71. PubMed ID: 31610267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanotechnology Strategies for the Analysis of Circulating Tumor DNA: A Review.
    Chen X; Wang L; Lou J
    Med Sci Monit; 2020 Mar; 26():e921040. PubMed ID: 32200389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analytical performance evaluation of a commercial next generation sequencing liquid biopsy platform using plasma ctDNA, reference standards, and synthetic serial dilution samples derived from normal plasma.
    Verma S; Moore MW; Ringler R; Ghosal A; Horvath K; Naef T; Anvari S; Cotter PD; Gunn S
    BMC Cancer; 2020 Oct; 20(1):945. PubMed ID: 33004033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liquid biopsy for cancer screening, diagnosis, and treatment.
    Smania MA
    J Am Assoc Nurse Pract; 2020 Jan; 32(1):5-7. PubMed ID: 31913212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of incipient tumours by screening of circulating plasma DNA: hype or hope?
    Lenaerts L; Tuveri S; Jatsenko T; Amant F; Vermeesch JR
    Acta Clin Belg; 2020 Feb; 75(1):9-18. PubMed ID: 31578135
    [No Abstract]   [Full Text] [Related]  

  • 16. Dynamic Treatment Stratification Using ctDNA.
    Vidal J; Taus A; Montagut C
    Recent Results Cancer Res; 2020; 215():263-273. PubMed ID: 31605234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unveiling the impact of circulating tumor cells: Two decades of discovery and clinical advancements in solid tumors.
    Reduzzi C; Nicolo' E; Singhal S; Venetis K; Ortega-Franco A; de Miguel-Perez D; Dipasquale A; Gouda MA; Saldanha EF; Kasi PM; Jantus-Lewintre E; Fusco N; Malapelle U; Gandara DR; Rolfo C; Serrano MJ; Cristofanilli M;
    Crit Rev Oncol Hematol; 2024 Nov; 203():104483. PubMed ID: 39159706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic Power of DNA Methylation Classifiers for Early Detection of Cancer.
    Roy D; Tiirikainen M
    Trends Cancer; 2020 Feb; 6(2):78-81. PubMed ID: 32061307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beyond Standard Practice in Liquid Biopsy: Selective Venous Sampling.
    Damascelli B; Tichà V; Repetti E; Dorji T
    J Vasc Interv Radiol; 2021 May; 32(5):668-671. PubMed ID: 33621662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumor DNA in liquid biopsy: Current diagnostic limitation.
    Liu SC
    World J Gastroenterol; 2024 Apr; 30(15):2175-2178. PubMed ID: 38681986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.